Physician profile
Arthur Lyman
NPI 1235819749
$4,365.98
in general payments reported to CMS, 2019-2025
33 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $23.28 · 2024: $2,080 · 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,365.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $922.88 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $535.86 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $372.24 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $319.37 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $292.58 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $205.96 | 2024-2025 | Vyepti, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $184.63 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $174.96 | 2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $139.21 | 2024-2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $131.53 | 2024-2025 | Kisunla, Amyvid |
| Corium, LLC | $117.52 | 2024-2025 | Azstarys |
| Alnylam Pharmaceuticals INC. | $88.96 | 2025 | Onpattro |
| Emd Serono, INC. | $87.53 | 2025 | |
| Biogen, INC. | $86.27 | 2024-2025 | Vumerity, Zurzuvae, Skyclarys |
| Tg Therapeutics, INC. | $84.63 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $79.94 | 2024-2025 | Qelbree |
| Noven Therapeutics, LLC | $76.62 | 2024-2025 | Secuado, Xelstrym |
| Almatica Pharma LLC | $55.60 | 2024 | Loreev Xr |
| Alexion Pharmaceuticals, INC. | $50.35 | 2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $46.89 | 2024-2025 | Crexont, Rytary |
| Tris Pharma INC | $41.19 | 2024 | Dyanavel Xr |
| Novo Nordisk INC | $37.62 | 2025 | Wegovy |
| Eisai INC. | $33.07 | 2024-2025 | |
| Indivior INC. | $27.45 | 2024 | Sublocade |
| Grifols USA, LLC | $24.23 | 2025 | Gamunex-C |
| Catalyst Pharmaceuticals, INC. | $21.11 | 2024 | |
| Xeris Pharmaceuticals, INC. | $20.24 | 2025 | Keveyis |
| Acadia Pharmaceuticals INC | $20.12 | 2025 | Nuplazid |
| Noven Pharmaceuticals, INC. | $19.73 | 2024 | Xelstrym |
| Bausch Health US, LLC | $19.15 | 2024 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $18.29 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $16.69 | 2024 | Trintellix |
| Genentech USA, INC. | $13.56 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Lyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.